Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript

Bausch Health highlighted 12 consecutive quarters of top-line and bottom-line growth, with management emphasizing continued focus on revenue growth, EBITDA expansion, and cash flow. The company pointed to strength in Salix, Xifaxan, Solta, and international businesses as the main drivers. The discussion was upbeat but largely qualitative, with no new financial guidance or quantified catalysts disclosed.

Analysis

The message is not just that the operating curve is improving; it is that the company has shifted from a turnaround narrative to a self-funding compounding story. That matters because once the market believes EBITDA growth is durable, the equity stops trading like a levered special situation and starts trading more like a cash-flow asset with optionality on deleveraging and capital allocation. In the near term, that can compress the company’s cost of capital faster than the operating results alone would imply.

The second-order winner is likely the debt stack: sustained cash generation should tighten spreads across the capital structure, especially in the nearer maturities, even if absolute leverage remains elevated. The less obvious loser is any short-interest thesis predicated on a near-term liquidity event; each quarter of clean execution forces shorts to fund a longer duration trade while waiting for a catalyst that may not exist. The operational mix also suggests the company is increasingly dependent on a few high-conviction franchises, which raises the value of monitoring concentration risk rather than headline growth alone.

The key risk is that this becomes a “good enough” story rather than a re-rating story if investors conclude growth is mature and not accelerating. That would cap multiple expansion even as fundamentals improve. A more bearish setup would emerge only if one of the core drivers stalls for a quarter or two, because the market is likely extrapolating the streak; the reversal in sentiment could be fast if cash conversion weakens before the balance sheet visibly improves.

Consensus is probably underestimating how much incremental equity value can be created by a few quarters of steady execution at a levered healthcare name. The move may still be early, because the market tends to wait for proof that growth is durable before rewarding a re-rate. If that proof keeps arriving, the stock can move disproportionately versus the incremental earnings change, especially if refinancing windows open against a lower spread backdrop.

Key Decisions for Investors

• Go long BHC common for a 3-6 month horizon into the next print cycle; the setup is favorable if execution persists, with upside driven more by multiple expansion than by modest EPS revisions.
• Pair long BHC / short a slower-growth leveraged healthcare credit proxy over 1-2 quarters; thesis is that improving cash flow should tighten BHC spreads faster than peers, with less room for the short leg to re-rate positively.
• For existing longs, consider buying 3-6 month call spreads on BHC instead of stock if implied volatility is not excessive; this captures re-rating optionality while limiting downside if the streak stalls.
• Use any post-rally weakness in BHC to add, but only if the next quarter’s cash conversion remains intact; if operating momentum softens, the trade should be cut quickly because levered growth stories can de-rate in days, not months.